Premium
New Therapeutic Approaches to Antibody‐Mediated Rejection in Renal Transplantation
Author(s) -
Raghavaiah S,
Stegall MD
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.123
Subject(s) - transplantation , medicine , human leukocyte antigen , immunology , antibody , kidney transplantation , clinical pharmacology , intensive care medicine , pharmacology , antigen
Antibodies against donor human‐leukocyte antigen (HLA) are becoming increasingly recognized as a major barrier to kidney transplantation. Over the past decade, therapeutic protocols have been developed that show promise in overcoming this difficult immunologic hurdle; yet problems remain, including high rates of both early and late antibody‐mediated rejection (AMR). This review outlines our current understanding of AMR and evaluates newer therapies designed to either block antibody production or ameliorate its effect on the allograft. Clinical Pharmacology & Therapeutics (2011) 90 2, 310–315. doi: 10.1038/clpt.2011.123